Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 200-Day Moving Average – Should You Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.80 and traded as high as $4.52. Oramed Pharmaceuticals shares last traded at $4.32, with a volume of 162,435 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals has an average rating of “Hold”.

Oramed Pharmaceuticals Price Performance

The firm has a market capitalization of $176.80 million, a P/E ratio of 1.67 and a beta of 1.22. The stock’s 50-day simple moving average is $4.11 and its two-hundred day simple moving average is $3.80.

Insider Activity

In related news, COO Joshua Hexter sold 137,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total transaction of $611,020.00. Following the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Avraham Gabay sold 73,360 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the sale, the chief financial officer owned 671,785 shares in the company, valued at approximately $3,029,750.35. The trade was a 9.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Large investors have recently bought and sold shares of the business. Ritholtz Wealth Management bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth about $529,000. SB Capital Management Inc purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth approximately $5,415,000. Redwood Family Wealth LLC purchased a new stake in Oramed Pharmaceuticals in the fourth quarter worth $66,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 7,738 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 14,297 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.